Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice

Bousquet P, Feldman J, Schwarts J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 1984;230:232-236.

Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc. Hematol Agents Med. Chem. 2006;4:17-32.

Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. Clin. Toxicol. 2014;52:454-469.

Li, JK. Imidazoline I2 receptors: An update. Pharmacol. Ther. 2017;178:48-56.

Fenton, C, Keating, G M, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs 2006;6:477-496.

Reid JL. Rilmenidine: A clinical overview. Am. J. Hypertens. 2000;13:106S-111S.

Olmos G, Alemany R, Boronat MA, García-Sevilla JA. Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes. Ann. N.Y. Acad. Sci. 1999;881:144-160.

Li JX, Zhang Y. Imidazoline I2 receptors: target for new analgesics? Eur. J. Pharmacol. 2011;658:49-56.

Callado LF, Martín-Gomez JI, Ruiz J, Garibi J, and Meana JJ. Imidazoline I2 receptors density increases with the malignancy of human gliomas. J. Neurol., Neurosurg. Psychiatry 2004;75:785-787.

Regunathan S, Feinstein DL, Reis DJ. Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved? Ann. N.Y. Acad. Sci. 1999;881:410-419.

Ruíz J, Martín I, Callado LF, Meana JJ, Barturen F, García-Sevilla JA. Non-adrenoreceptor [3H] idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer’s disease. Neurosci. Lett. 1993;160:109-112.

García-Sevilla JA, Escribá PV, Walzer C, Bouras C, Guimón J. Imidazoline receptor proteins in brains of patients with Alzheimer’s disease. Neurosci. Lett. 1998;247:95-98.

Gargalidis-Moudanos C, Pizzinat N, Javoy-Agid F, Remaury A, Parini A. I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson’s disease. Neurochem. Int. 1997;30:31-36.

Meana JJ, Barturen, F, Martín I, García-Sevilla JA. Evidence of increased non-adrenoreceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol. Psychiatry 1993;34:498-501.

García-Sevilla JA, Escribá PV, Sastre, et al. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch. Gen. Psychiatry 1996;53:803-810.

Smith KL, Jessop DS, Finn DP. Modulation of stress by imidazoline binding sites: implications for psychiatric disorders. Stress 2009;12:97-114.

Comi E, Lanza M, Ferrari F, Mauri V, Caselli G, Rovati LC. Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis. J. Pain Res. 2017;10:1033-1043.

Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Ann. Rev. Pharmacol. Toxicol. 1996;36:511-544.

Dardonville C, Rozas I. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med. Res. Rev. 2004;24:639-661.

Boronat MA, Olmos G, García-Sevilla JA. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Br. J. Pharmacol. 1998;125:175-185.

McDonald GR, Olivieri A, Ramsay RR, Holt A. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase B. Pharmacol. Res. 2010;62:475-488.

Casanovas A, Olmos G, Ribera J, Boronat MA, Esquerda JE, García-Sevilla JA. Induction of reactive astrocytosis and prevention of motoneuron cell death by the I2-imidazoline receptor ligand LSL 60101. Br. J. Pharmacol. 2000;130:1767-1776.

Gustafson I, Westerberg E, Wieloch T. Protection against ischemia-induced neuronal damage by the α2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 1990;10:885-894.

Qiu WW, Zheng RY. Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine. Neurosci. Bull. 2006;22:187-191.

Gilad GM, Gilad VH. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci. Lett. 2000;296:97-100.

Han Z, Xiao MJ, Shao B, Zheng RY, Yang GY, Jin K. Attenuation of ischemia induced rat brain injury by 2-(-2-benzofuranyl)-2-imidazoline, a high selectivity ligand for imidazoline I(2) receptors. Neurol. Res. 2009;31:390-395.

Maiese K, Pek L, Berger SB, Reis D J. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J. Cereb. Blood Flow Metab. 1992;12:53-63.

Jiang SX, Zheng RY, Zheng JQ, Li XL, Han Z, Hou ST. Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline (I)2 receptor antagonists. Eur. J. Pharmacol. 2010;629:12-19.

Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res. 1998;780:270–293.

Olmos G, Alemany R, Escriba PV, García-Sevilla JA. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br. J. Pharmacol. 1994;111:997-1002.

Rodríguez-Arellano JJ, Parpura V, Zorec R, Verkhratsky, A. Astrocytes in physiological aging and Alzheimer’s disease. Neuroscience 2016;323:170-182.

Martín-Gómez JI, Ruíz J, Barrondo S, Callado, LF, Meana JJ. Opposite changes in Imidazoline I2 receptors and α2-adrenoceptors density in rat frontal cortex after induced gliosis. Life Sci. 2005;78:205-209.

Sica DA. Alpha 1-adrenergic blockers: current usage considerations. J. Clin. Hypertens. (Greenwich) 2005;7:757-762.

Abás S, Estarellas C, Luque FJ, Escolano C. Easy access to (2-imidazolin-4-yl)phosphonates by a microwave assisted multicomponent reaction. Tetrahedron 2015;71:2872-2881.

Abás S, Erdozain AM, Keller B et al. Neuroprotrective effects of a structurally new family of high affinity imidazoline I2 receptors ligands. ACS Chem. Neurosci. 2017;8:737-742.

Morley JE, Farr SA, Kumar VB, Armbrecht HJ. The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease. Curr. Pharm. Des. 2012;18:1123-1130.

Di L, Kerns EH, Fan K, McConnell OJ, Carter G. T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003;38:223–232.

McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br. J. Pharmacol. 2015;172:3189-3193.

Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res.1988;31:47-59.

Ferrari F, Fiorentino S, Mennuni L, Garofalo P, Letari O, Mandelli S, Giordani A, Lanza M, Caselli G. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. 2011;4:111-125.

Jackson HC, Ripley TL, Dickinson SL, Nutt DJ. Anticonvulsant activity of the imidazoline 6,7-benzoidazoxan. Epilepsy Res. 1991;9(2):121-126.

Min JW, Peng BW, He X, Zhang Y, Li JX. Gender difference in epileptogenic effects of 2-BFI and BU224 in mice. Eur J Pharmacol. 2013;718(1-3):81-86.

Keller B, García-Sevilla JA. Immunodetection and subcellular distribution of imidazoline receptor proteins with three antibodies in mouse and human brains: Effects of treatments with I1- and I2-imidazoline drugs. J Psychopharmacol. 2015;29(9):996-1012.

Thorn DA, An XF, Zhang Y, Pigini M, Li, JX. Characterization of the hypothermic effects of imidazoline I2 receptor agonist in rats. Br. J. Pharmacol. 2009;166:1936-1945.

Craven JA, Conway EL. Effects of alpha 2-adrenoceptor antagonists and imidazoline 2-receptor ligands on neuronal damage in global ischemia in the rat. Clin. Exp. Pharmacol. Physiol. 1997;24:204-207.

Illevich UM, Zornow MH, Choi KT, Scheller M, Strnat MA. Effects of hypothermic metabolic suppression on hippocampal glutamate concentrations after transient global cerebral ischemia. Anesth. Analg. 1994;78:905-911.

Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem. Res. 2009;34:639-659.

Pallàs M. Senescence-accelerated mice P8: a tool to study brain aging and Alzheimer’s disease in a mouse model. ISRN Cell Biol. 2012:1-12.

Archer J. Tests for emotionality in rats and mice: A review. Anim. Behav. 1973;21:205-235.

Dawson GR, Tricklebank MD. Use of the elevated plus maze in the search for novel anxiolític agents. Trends Pharmacol. Sci. 1995;16:33-36.

Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn. Process. 2012;13:93-110.

Gao H-M, Zhou H, Hong JS. Oxidative Stress, Neuroinflammation, and Neurodegeneration. In: Peterson P. K., Toborek M. (Eds) Neuroinflammation and Neurodegeneration, 2014; pp. 81-104, Springer, New York, NY.

Fujibayashi Y, Yamamoto S, Waki A, Konishi J, Yonekura Y. Increased mitochondrial DNA deletion in the brain of SAMP8, a mouse model for spontaneous oxidative stress brain. Neurosci. Lett. 1998:254:109-112.

Sureda FX, Gutierrez-Cuesta J, Romeu M, Mulero M, Canudas AM, Camins A, Mallol J,Pallàs M. Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Exp. Gerontol. 2006;41:360-367.

Gutierrez-Cuesta J, Sureda FX, Romeu M, Canudas AM, Caballero B, Coto-Montes A, Camins A, Pallàs M. Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8. J. Pineal Res. 2007;42:394-402.

Griñán-Ferré C, Palomera-Avalos V, Puigoriol-Illamola D, Camins A, Porquet D, Plà V, Aguado F, Pallàs M. Behaviour and cognitive changes correlated with hippocampal neuroinflammaging and neuronal markers in SAMP8, a model of accelerated senescence. Exp. Gerontol. 2016;80:57-69.

Griñan-Ferré C, Puigoriol-Illamola D, Palomera-Ávalos, V. et al. Environmental enrichment modified epigenetic mechanisms in SAMP8 mouse hippocampus by reducing oxidative stress and inflammaging and achieving neuroprotection. Front. Aging Neurosci. 2016;8:1-12.

Gao L, Tian S, Gao H, Xu Y. Hypoxia increases Abeta-induced tau phosphorylation by calpain and promotes behavioral consequences in AD transgenic mice. J. Mol. Neurosci. 2013;51:138-147.

Kimura T, Ishiguro K, Hisanaga S. Physiological and pathological phosphorylation of tau by Cdk5. Front. Mol. Neurosci. 2014;7:1-10.

Keller B, García-Sevilla JA. Regulation of hippocampal Fas receptor and death-inducing signaling complex after kainic acid treatment in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2015;3:63:54-62.

Cheng EH, Wei MD, Weiler S, Flavell RA. Mak TW, Lindster T, Korsmeyer SJ. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell. 2001;8:705-711.

Martin LJ. Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. Pharmaceuticals. 2010;3:839-915.

Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem. 2001;76:1–10.

Hardingham GE, Bading H. Synaptic versus extransynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010;11:682-696.

Imajo M, Tsuchiya Y, Nishida E. Regulatory mechanisms and functions of MAP Kinase signalling pathways. IUBMB Life 2006;58:312-317.

Cruz CD, Cruz F. The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr. Neuropharmacol. 2007;5:244-252.

Hyman BT, Elvhage TE, Reiter J. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am. J. Pathol. 1994;144:565-572.

Russo C, Dolcini V, Salis S, Venezia V, Zambrano N, Russo, T, Schettini G. Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer’s disease brain. J. Biol. Chem. 2002; 277: 35282-35288.

Kulich SM, Chu CT. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson’s disease. J. Neurochem. 2001;77:1058-1066.

Montolio M, Gregori-Puigjané E, Pineda D, Mestres J, Navarro P. Identification of small molecule inhibitors of amyloid β-induced neuronal apoptosis acting through the imidazoline I(2) receptor. J. Med. Chem. 2012;55(22):9838-46.

Zhang F, Ding T, Yu L, Zhong Y, Dai H, Yan M. Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells. J Pharm Pharmacol. 2012;64(1):120-7.

Xuanfei L, Hao C, Zhujun Y, Yanming L, Jianping. Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway. Oncotarget. 2017;8(13):21015-21030.

García-Fuster, MJ, Miralles, A, and García-Sevilla, JA. Effects of opiate drugs on Fas-Associated Protein with Death Domain (FADD) and effector caspases in the rat brain: Regulation by the ERK1/2 MAP kinase pathway. Neuropsychopharmacology 2007;32:399-411.

Ramos-Miguel A, García-Fuster MJ, Callado LF, La Harpe R, Meana JJ, García-Sevilla JA. Phosphorylation of FADD (Fas-associated death domain protein) at serine 194 is increased in the prefrontal cortex of opiate abusers: relation to mitogen activated protein kinase, phosphoprotein enriched in astrocytes of 15 kDa, and Akt signaling pathways involved in neuroplasticity. Neuroscience 2009;161:23-38.

Papaliagkas V, Anogianaki A, Anogianakis G, Ilonidis G. The proteins and the mechanisms of apoptosis: A mini-review of the fundamentals. Hippokratia 2007;11:108-113.

Ramos-Miguel A, García-Sevilla JA, Barr A. et al. Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample. Mol. Neurodegener. 2017;12:26.

Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain Fas and initiates apoptosis. Cell. 1997;81:505-512.

Scott FL, Stec B, Pop C, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009; 457:1019-1022.

Alappat EC, Feig C, Boyerinas B. et al. Phosphorylation of FADD at serine 194 by CKIα regulates its nonapoptotic activities. Mol. Cell. 2005;19:321-332.

O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu. Rev. Neurosci. 2011;34:185-204.

Gralle M, Botelho MG, Wouters FS. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J. Biol. Chem. 2016; 284:15016-15025.

Lichtenthaler SF. Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking. Curr. Alzheimer Res. 2012;9:165-177.

El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: An Enzyme Candidate to Slow the Progression of Alzheimer’s Disease. Am. J. Pathol. 2008;172:1342-1354.